dc.contributor.author
Aziz, Mubashir
dc.contributor.author
Sarfraz, Muhammad
dc.contributor.author
Khurrum Ibrahim, Muhammad
dc.contributor.author
Ejaz, Syeda Abida
dc.contributor.author
Zehra, Tasneem
dc.contributor.author
Ogaly, Hanan A.
dc.contributor.author
Arafat, Mosab
dc.contributor.author
Al-Zahrani, Fatimah A. M.
dc.contributor.author
Li, Chen
dc.date.accessioned
2024-03-15T08:27:29Z
dc.date.available
2024-03-15T08:27:29Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/42839
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-42555
dc.description.abstract
Cancer stands as a significant global cause of mortality, predominantly arising from the dysregulation of key enzymes and DNA. One strategic avenue in developing new anticancer agents involves targeting specific proteins within the cancer pathway. Amidst ongoing efforts to enhance the efficacy of anticancer drugs, a range of crucial medications currently interact with DNA at the molecular level, exerting profound biological effects. Our study is driven by the objective to comprehensively explore the potential of two compounds: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (A01) and 5-fluoro-1H-pyrimidine-2,4-dione (A02). These compounds have demonstrated marked efficacy against breast and cervical cancer cell lines, positioning them as promising anticancer candidates. In our investigation, A01 has emerged as a particularly potent candidate, with its potential bolstered by corroborative evidence from lactate dehydrogenase release and caspase-3 activity assays. On the other hand, A02 has exhibited remarkable anticancer potential. To further elucidate their molecular mechanisms and interactions, we employed computational techniques, including molecular docking and molecular dynamics simulations. Notably, our computational analyses suggest that the A01-DNA complex predominantly interacts via the minor groove, imparting significant insights into its mechanism of action. While earlier studies have also highlighted the anticancer activity of A01, our research contributes by providing a deeper understanding of its binding mechanisms through computational investigations. This knowledge holds potential for designing more effective drugs that target cancer-associated proteins. These findings lay a robust groundwork for future inquiries and propose that derivatives of A01 could be synthesized as potent bioactive agents for cancer treatment. By elucidating the distinctive aspects of our study’s outcomes, we address the concern of distinguishing our findings from those of prior research.
en
dc.format.extent
28 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Breast cancer
en
dc.subject
Drug interactions
en
dc.subject
Transcription factors
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.title
Evaluation of anticancer potential of tetracene-5,12-dione (A01) and pyrimidine-2,4-dione (A02) via caspase 3 and lactate dehydrogenase cytotoxicity investigations
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
e0292455
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0292455
dcterms.bibliographicCitation.journaltitle
PLoS ONE
dcterms.bibliographicCitation.number
12
dcterms.bibliographicCitation.volume
18
dcterms.bibliographicCitation.url
https://doi.org/10.1371/journal.pone.0292455
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1932-6203
refubium.resourceType.provider
WoS-Alert